AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
NORTH CHICAGO - AbbVie today announced new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further demonstrated the long-term efficacy and safety profile of RINVOQ ...
Source: marketscreener.com